مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

440
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

329
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

SAFETY AND EFFICACY OF LOCALLY MANUFACTURED PEGYLATED INTERFERON IN HEPATITIS C PATIENTS

Pages

  306-312

Abstract

 Background: To evaluate the safety and effectiveness of locally produced pegylated interferon-a2a in treatment-naïve patients with chronic HEPATITIS C.Methods: All treatment-naïve patients diagnosed with chronic HEPATITIS C who referred to two university based outpatient clinics in Tehran from December 2007 to May 2008 were enrolled. Exclusion criteria included the presence of a debilitating disease, decompensated cirrhosis, or refusal to participate in the study. Patients were treated with 180 mg pegylated interferon-a2a (Pegaferon) weekly and 800-1200 mg RIBAVIRIN daily for 24 or 48 weeks depending on genotype and weight. Viral and biochemical response and adverse drug reactions were recorded.Results: A total of 108 patients were enrolled; 63 with genotype 1 and 45 with genotypes 2 and 3. The mean age of the patients was 39 years (range: 19-65). Ninety-seven patients completed the study and 76 achieved sustained viral response. The sustained viral response among patients completing the study was 67% for genotype 1 and 95% for genotypes 2 and 3. Adverse events were well tolerated and none led to discontinuation of treatment, however dose adjustment was necessitated in 16 patients. The most common adverse events were fatigue (73.5%), poor appetite (66.2%), and feverishness (57.4%). The mean hemoglobin drop was 2.9 g/dL.Conclusions: Locally produced PEG-IFN in Iran is safe and effective in treatment-naïve chronic HEPATITIS C. Clinical Trials. gov identifier: NCT01137383

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    JABARI, HOSSEIN, BAYATIAN, A.A., SHARIFI, A.H., ZAER REZAEI, H., FAKHARZADEH, E., ASADI, REYHANEH, ZAMINI, H., SHAHZAMANI, K., MERAT, SH., & NASIRI TOUSI, M.. (2010). SAFETY AND EFFICACY OF LOCALLY MANUFACTURED PEGYLATED INTERFERON IN HEPATITIS C PATIENTS. ARCHIVES OF IRANIAN MEDICINE, 13(4), 306-312. SID. https://sid.ir/paper/280575/en

    Vancouver: Copy

    JABARI HOSSEIN, BAYATIAN A.A., SHARIFI A.H., ZAER REZAEI H., FAKHARZADEH E., ASADI REYHANEH, ZAMINI H., SHAHZAMANI K., MERAT SH., NASIRI TOUSI M.. SAFETY AND EFFICACY OF LOCALLY MANUFACTURED PEGYLATED INTERFERON IN HEPATITIS C PATIENTS. ARCHIVES OF IRANIAN MEDICINE[Internet]. 2010;13(4):306-312. Available from: https://sid.ir/paper/280575/en

    IEEE: Copy

    HOSSEIN JABARI, A.A. BAYATIAN, A.H. SHARIFI, H. ZAER REZAEI, E. FAKHARZADEH, REYHANEH ASADI, H. ZAMINI, K. SHAHZAMANI, SH. MERAT, and M. NASIRI TOUSI, “SAFETY AND EFFICACY OF LOCALLY MANUFACTURED PEGYLATED INTERFERON IN HEPATITIS C PATIENTS,” ARCHIVES OF IRANIAN MEDICINE, vol. 13, no. 4, pp. 306–312, 2010, [Online]. Available: https://sid.ir/paper/280575/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button